A robust control system for targeting melanoma by a supermolecular DDMC/paclitaxel complex

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Biology

Background:

• B16F10 melanoma cells exhibit resistance to paclitaxel (PTX).
• Developing drug delivery systems to overcome cancer drug resistance is crucial.
• Allosteric systems offer potential for controlled drug release and enhanced efficacy.

Purpose of the Study:

• To synthesize and characterize a DEAE-dextran-MMA copolymer (DDMC)-paclitaxel (PTX) conjugate.
• To evaluate the anticancer activity of the DDMC-PTX conjugate against PTX-resistant B16F10 melanoma cells.
• To investigate the stability and mechanism of action of the conjugate in the tumor microenvironment.

Main Methods:

• Preparation of a DDMC-PTX conjugate using PTX as guest and DDMC as host.
• Assessment of anticancer activity using B16F10 melanoma cell line.
• Evaluation of system stability in the tumor microenvironment using BIBO stability.
• Analysis of the system using transfer function, block diagrams, and Hill equation kinetics.

Main Results:

• The DDMC-PTX conjugate demonstrated excellent anticancer activity against PTX-resistant B16F10 cells.
• The conjugate's efficacy followed the Hill equation, indicating a cooperative binding mechanism.
• The allosteric system exhibited robustness and stability in the tumor microenvironment.
• The cell death rate was more dependent on the Hill coefficient (n) than the Michaelis constant (Km), suggesting an "induced fit model".

Conclusions:

• The DDMC-PTX conjugate is a stable and effective anticancer agent against drug-resistant melanoma.
• The conjugate's mechanism of action aligns with an "induced fit model" in its interaction with tubulin.
• This supramolecular drug delivery system shows potential for overcoming cancer drug resistance and improving therapeutic outcomes.